SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities.

Szczegóły

Tytuł:: SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities.
Autorzy:: Casadevall A; Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.
Henderson JP; Departments of Medicine and Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Joyner MJ; Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Pirofski LA; Departments of Medicine and Microbiology and Immunology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
Źródło:: The Journal of clinical investigation [J Clin Invest] 2021 Apr 01; Vol. 131 (7).
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural
Język:: English
Imprint Name(s):: Publication: 1999- : Ann Arbor, MI : American Society for Clinical Investigation
Original Publication: New Haven [etc.] American Society for Clinical Investigation.
MeSH Terms:: COVID-19/*therapy
COVID-19/*virology
SARS-CoV-2/*immunology
Antibodies, Neutralizing/biosynthesis ; Antibodies, Neutralizing/blood ; Antibodies, Viral/biosynthesis ; Antibodies, Viral/blood ; COVID-19/immunology ; Genome, Viral ; Host Microbial Interactions/immunology ; Humans ; Immune Evasion ; Immunization, Passive/adverse effects ; Models, Immunological ; Pandemics ; SARS-CoV-2/genetics ; SARS-CoV-2/pathogenicity ; COVID-19 Serotherapy
References:: Science. 2020 Aug 21;369(6506):1014-1018. (PMID: 32540904)
N Engl J Med. 2021 Jan 21;384(3):238-251. (PMID: 33332778)
Eur J Clin Microbiol Infect Dis. 2017 Feb;36(2):361-371. (PMID: 27848039)
Nature. 2021 Apr;592(7853):277-282. (PMID: 33545711)
Cell. 2020 Oct 29;183(3):739-751.e8. (PMID: 32991842)
JAMA. 2021 Apr 6;325(13):1261-1262. (PMID: 33571363)
Clin Infect Dis. 2010 Jul 15;51(2):185-8. (PMID: 20528472)
Virology. 2004 Jan 20;318(2):608-12. (PMID: 14972528)
J Virol. 2005 Apr;79(7):3962-8. (PMID: 15767398)
Grant Information:: R01 AI123654 United States AI NIAID NIH HHS; R01 DK111930 United States DK NIDDK NIH HHS; R01 HL059842 United States HL NHLBI NIH HHS; R35 HL139854 United States HL NHLBI NIH HHS; R01 AI143453 United States AI NIAID NIH HHS; R01 AI052733 United States AI NIAID NIH HHS; UL1 TR002556 United States TR NCATS NIH HHS; R56 DK111930 United States DK NIDDK NIH HHS
Substance Nomenclature:: 0 (Antibodies, Neutralizing)
0 (Antibodies, Viral)
Entry Date(s):: Date Created: 20210223 Date Completed: 20210415 Latest Revision: 20221207
Update Code:: 20240105
PubMed Central ID:: PMC8011895
DOI:: 10.1172/JCI148832
PMID:: 33621214
: Czasopismo naukowe

Informacja